CLP-3094, a potent inhibitor targeting the binding function 3 (BF3) site of androgen receptor (AR), inhibits AR transcriptional activity with IC50 of 4 μM, also is a selective, potent GPR142 antagonist.
[1] Munuganti RS, et al. J Med Chem. 2013 Feb 14;56(3):1136-48.
















